Tolazoline hydrochloride


Generic Medicine Info
Indications and Dosage
Endotracheal
Pulmonary hypertension
Child: Neonate: 200 mcg/kg diluted with 0.5-1 ml of sodium chloride 0.9% for inj.

Intravenous
Pulmonary hypertension
Child: Neonate: Initially 1 mg/kg by IV inj over 2-5 min, followed by continuous IV infusion of 200 mcg/kg/hr (diluted with glucose 5% or sodium chloride 0.9%) if required. Monitor BP closely. Doses >300 mcg/kg/hr associated with cardiotoxicity and renal failure.

Oral
Peripheral vascular disease
Adult: 25-50 mg 4 times daily.

Parenteral
Peripheral vascular disease
Adult: Up to 50 mg by SC, IM, IV or slow intra-arterial inj.
Contraindications
Peptic ulcer, ischaemic heart disease, hypotension, stroke.
Special Precautions
Mitral stenosis. May activate stress ulcer. Pretreatment with antacid may prevent GI bleed in neonates. Pregnancy.
Adverse Reactions
Piloerection, headache, flushing, nausea, vomiting, diarrhoea, epigastric pain, tachycardia, cardiac arrhythmias, tingling, chilliness, shivering, sweating, oliguria, haematuria, metabolic alkalosis, MI, GI haemorrhage, burning sensation in the limb with intra-arterial inj.
Potentially Fatal: Blood dyscrasias, cardiotoxicity, renal failure.
Overdosage
Symptoms: Increased pilomotor activity, peripheral vasodilatation, skin flushing, hypotension and shock. Management: Admin IV fluid and place the patient's head low in the treatment of hypotension. Epinephrine should not be used as high-dose tolazoline may result in further reduction in BP, followed by an exaggerated rebound.
Drug Interactions
Disulfiram-like reaction with alcohol. Decreased pulmonary vasodilatory effects of tolazoline with H2-receptor antagonists. Increased risk of paradoxical hypotension with sympathomimetics.
Action
Description: Tolazoline is a direct peripheral vasodilator with some α-adrenoceptor-blocking activity. Besides stimulating smooth muscle in the GI tract and increasing GI secretion, it can also cause mydriasis and heart stimulation.
Pharmacokinetics:
Excretion: Excreted in urine mainly as unchanged drug. Half-life in neonates: 3-10 hr.
Storage
Endotracheal:
Store between 15-30°C (59-86°F).
Intravenous:
Store between 15-30°C (59-86°F).
Parenteral:
Store between 15-30°C (59-86°F).
Disclaimer: This information is independently developed by MIMS based on Tolazoline hydrochloride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in